HFpEF (heart failure with preserved ejection fraction) with master cardiologist, Dr Clyde Yancy MD, Chief of Cardiology and Professor of Medicine (Cardiology) and Medical Social Sciences, Northwestern, Feinberg School of Medicine. Topics include: pathophysiology, HFpEF phenotypes, how to interpret a borderline ejection fraction, evidence based therapies, diuretics, and future directions (pulmonary artery monitors, intra-atrial shunts, ARNI compounds), and more! Full show notes available at http://thecurbsiders.com/podcast. Join our mailing list and receive a PDF copy of our show notes every Monday. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Credits Written and produced by: Paul Williams MD, FACP; Sarah Phoebe Roberts MPH Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP; Stuart Brigham MD Show Notes: Justin Berk MD, MPH, MBA; and Beth Garbitelli MS1 Infographics: Beth Garbitelli MS1 Editor: Matthew Watto MD, FACP Guest: Clyde Yancy MD, MSc, MACC, FAHA, MACP, FHFSA Time Stamps 00:00 Thanks to our producers Sarah Phoebe Roberts, Beth Garbitelli and Justin Berk 00:50 Intro and guest bio 04:00 Guest one liner, career advice 08:20 Ms Diana Stolic has HFpEF. What’s the difference in HFpEF and diastolic dysfunction?   11:33 How should we think about borderline ejection fraction? 15:24 Pathophysiology and Phenotypes of HFpEF 18:57 More on the pathophysiology of HFpEF (nitric oxide, fibrosis, inflammatory signaling) 21:00 Are there morbidity and mortality differences for HFpEF versus HFrEF? 24:45 What historical factors are most important in HFpEF? 27:50 Pulmonary artery monitors for HFpEF 29:00 Does Diuretic therapy differ in HFpEF and HFrEF? 33:44 Ischemic workup for new HFpEF 35:33 Right heart cath for HFpEF 36:53 Future of HFpEF 41:04 Will ARNI compounds work for HFpEF? What are the current medications for HFpEF? 45:20 SGLT2 inhibitors for heart failure 46:30 Outro